Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL) Peptide
Quick Overview for Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL) Peptide (ABIN937698)
Target
Origin
Source
Application
-
-
Peptide Type
- Synthetic
-
Sequence
- EDGGEESGAE ESGPEESGPE ELGAEEEMEA GRPRPVLRSV NSREPSQVIF
-
Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of VHL antibody,
Alternative Names: VHL control peptide, VHL antibody Blocking Peptide, Anti-VHL Blocking Peptide, von Hippel-Lindau tumor suppressor Blocking Peptide, HRCA1 Blocking Peptide, RCA1 Blocking Peptide, VHL1 Blocking Peptide
-
-
-
-
Application Notes
- Optimal conditions should be determined by the investigator
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
-
Buffer
- PBS
-
Handling Advice
- Avoid repeated freeze/thaw cycles.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20 °C long term.
-
-
- VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
-
Background
- Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
-
Molecular Weight
- 19 kDa
Target
-